ArticleCureus2025
An Interesting Outcome of Central Sleep Apnea With Phrenic Nerve Stimulation Therapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central sleep apnea (CSA) is secondary to inadequate ventilation during sleep, causing individuals to experience repeated hypoxic episodes with long-term consequences of oxygen desaturation, such as arrhythmias, hypertension, congestive heart failure, stroke, coronary artery disease, cognitive issues, increased risk of accidents, type 2 diabetes, and worsening Parkinson's disease. The phrenic nerve stimulator, remedē System (ZOLL Respicardia, Inc., Minnetonka, MN) is indicated as treatment for moderate-to-severe CSA in adults. It works by stimulating the phrenic nerve, which, in turn, causes the diaphragm to contract and helps restore normal breathing patterns during sleep. A 60-year-old male with obesity, essential hypertension, seizure, and stroke with biventricular hemorrhage secondary to cerebral aneurysm was seen in a sleep medicine clinic for sleep apnea. His polysomnogram showed severe primary CSA with an apnea-hypopnea index (AHI) of 63.4 per hour, central apnea index of 51.8 per hour, and lowest oxygen saturation of 73% with nocturnal hypoxemia of 6.9 minutes below 88% oxygen saturation. After remedē System implantation, the patient's WatchPAT® sleep study showed a residual AHI of 11.4 per hour, CSA index of 0.0 per hour, and lowest oxygen saturation 84% with nocturnal hypoxemia of 3.2 minutes below 88% oxygen saturation. In our unique case, we found significant improvement of AHI and resolution of CSA along with improvement in verbal fluency, mathematical skills, and cognition with the use of remedē System.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.